Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study
Por:
Chari, A, van de Donk, NWCJ, Dholaria, B, Weisel, K, Mateos, MV, Goldschmidt, H, Martin, TG, Morillo, D, Reece, D, Rodríguez-Otero, P, Bhutani, M, D'Souza, A, Oriol, A, Rosiñol, L, Bahlis, NJ, Vishwamitra, D, Skerget, S, Verona, RI, Bakshi, K, Kang, LJ, Prior, TJ, Vandenberk, L, Tolbert, J, Lee, SM, Smit, MD and Wäsch, R
Publicada:
11 dic 2025
Ahead of Print:
1 dic 2025
Resumen:
Talquetamab, a G protein-coupled receptor class C group 5 member D-targeting bispecific antibody for relapsed/refractory multiple myeloma (R/R MM), plus daratumumab, may lead to deeper and more durable responses than either therapy alone. In the phase 1b TRIMM-2 study, patients with R/R MM (at least 3 previous lines of therapy or double refractory to a proteasome inhibitor and an immunomodulatory drug) received subcutaneous talquetamab 0.4 mg/kg weekly (QW; "QW cohort") or 0.8 mg/kg every other week (Q2W cohort) plus daratumumab 1800 mg per the approved schedule. The primary end point was safety. Secondary end points included overall response and duration of response. Progression-free survival was an exploratory end point. Sixty-five patients (median 5 previous lines of therapy; 61.5% triple-class refractory; 24.6% bispecific antibody exposed) received talquetamab plus daratumumab (QW, n = 14; Q2W, n = 51; median follow-up of 18.6 months). Most common adverse events were oral events, skin events, cytokine release syndrome, and infections. Grade 3 or 4 events occurred in 81.5%. Two patients had dose-limiting toxicities, both in the Q2W cohort (grade 3 stomatitis/oral mucositis, and grade 3 maculopapular rash). Responses occurred in 71.4% (QW cohort) and 82.4% (Q2W cohort) of patients. Median progression-free survival was 23.3 and 21.2 months, respectively, in each cohort. Pharmacodynamic results suggest the immunomodulatory action of daratumumab contributes to a conducive environment for talquetamab by reducing immunosuppressive cells. Talquetamab plus daratumumab demonstrated promising efficacy outcomes in patients with heavily pretreated disease, with a safety profile consistent with each agent as monotherapy. This trial was registered at www.clinicaltrials.gov as #NCT04108195.
Filiaciones:
Chari, A:
Univ Calif San Francisco, Dept Hematol Oncol Myeloma, San Francisco, CA USA
van de Donk, NWCJ:
Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Canc Ctr Amsterdam, Dept Hematol, Amsterdam, Netherlands
Dholaria, B:
Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA
Weisel, K:
Univ Med Ctr Hamburg Eppendorf, Dept Oncol, Hematol, Hamburg, Germany
Mateos, MV:
Hosp Univ Salamanca, Inst Invest Biomed Salamanca, Ctr Invest Canc, Dept Hematol, Salamanca, Spain
Goldschmidt, H:
Univ Clin Heidelberg, Dept Internal Med Hematol Oncol & Rheumatol 5, Heidelberg, Germany
Martin, TG:
Univ Calif San Francisco, Dept Hematol Oncol Myeloma, San Francisco, CA USA
Morillo, D:
Univ Hosp Fdn Jimenez Diaz, Dept Hematol, START Madrid FJD Early Phase Unit, Madrid, Spain
Reece, D:
Princess Margaret Canc Ctr, Canc Clin Res Unit, Toronto, ON, Canada
Rodríguez-Otero, P:
Clin Univ Navarra, Ctr Invest Med Aplicada, Ctr Invest Biomed Red Canc, Cent Unit Clin Trials,Inst Invest Sanit Navarra, Pamplona, Spain
Bhutani, M:
Atrium Hlth Wake Forest Univ, Levine Canc Inst, Sch Med, Dept Hematol & Med Oncol Canc, Charlotte, NC USA
D'Souza, A:
Med Coll Wisconsin, Div Hematol Oncol, Milwaukee, WI USA
:
Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Clin Res Support Unit, Barcelona, Spain
Hosp Badalona Germans Trias & Pujol, Inst Josep Carreras, Barcelona, Spain
Rosiñol, L:
Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer, Dept Hematol, Amyloidosis & Myeloma Unit, Barcelona, Spain
Bahlis, NJ:
Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada
Vishwamitra, D:
Johnson & Johnson, Spring House, PA USA
Skerget, S:
Johnson & Johnson, Spring House, PA USA
Verona, RI:
Johnson & Johnson, Spring House, PA USA
Bakshi, K:
Johnson & Johnson, Spring House, PA USA
Kang, LJ:
Johnson & Johnson, Spring House, PA USA
Prior, TJ:
Johnson & Johnson, Spring House, PA USA
Vandenberk, L:
Johnson & Johnson, Antwerp, Belgium
Tolbert, J:
Johnson & Johnson, Spring House, PA USA
Lee, SM:
Johnson & Johnson, Spring House, PA USA
Smit, MD:
Johnson & Johnson, Leiden, Netherlands
Wäsch, R:
Univ Freiburg, Fac Med, Med Ctr, Dept Med Hematol Oncol & Stem Cell Transplantat 1, Freiburg, Germany
Green Submitted, hybrid
|